Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Feb
26
Today In Oncology
Advanced Nonsquamous NSCLC FDA Grants Accelerated Approval to Zongertinib
Long-Term Health Risks for Testicular Cancer Survivors Differ by Chemotherapy Regimen
Cancer Diagnoses During COVID-19 Pandemic: Impact on 1-Year Cause-Specific Survival
‘Prostate Screening Saved My Life’—Is That Really True In Most Cases?
Effect of Medicaid Expansion on Diagnosis, Treatment, and Outcomes in NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo